Abstract
Background: SIRT2 belongs to a class III of Histone Deacetylase (HDAC) and has crucial roles in neurodegeneration and malignancy.
Objective: The objective of this study is to discover structurally novel natural-product-derived SIRT2 inhibitors.
Methods: Structure-based pharmacophore modeling integrated with validated QSAR analysis was implemented to discover structurally novel SIRT2 inhibitors from the natural products database. The targeted QSAR model combined molecular descriptors with structure-based pharmacophore capable of explaining bioactivity variation of structurally diverse SIRT2 inhibitors. Manually built pharmacophore model, validated with receiver operating characteristic curve, and selected using the statistically optimum QSAR equation, was applied as a 3Dsearch query to mine AnalytiCon Discovery database of natural products.
Results: Experimental in vitro testing of highest-ranked hits identified asperphenamate and salvianolic acid B as active SIRT2 inhibitors with IC50 values in low micromolar range.
Conclusion: New chemical scaffolds of SIRT2 inhibitors have been identified that could serve as a starting point for lead-structure optimization.
Keywords: SIRT2, cancer, neurodegenerative diseases, pharmacophore, QSAR, virtual screening, natural products.
Anti-Cancer Agents in Medicinal Chemistry
Title:Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure- Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses
Volume: 21 Issue: 16
Author(s): Mohammad A. Khanfar* Saja Alqtaishat
Affiliation:
- College of Pharmacy, Alfaisal University, Al Takhassusi Rd, Riyadh11533,Saudi Arabia
Keywords: SIRT2, cancer, neurodegenerative diseases, pharmacophore, QSAR, virtual screening, natural products.
Abstract:
Background: SIRT2 belongs to a class III of Histone Deacetylase (HDAC) and has crucial roles in neurodegeneration and malignancy.
Objective: The objective of this study is to discover structurally novel natural-product-derived SIRT2 inhibitors.
Methods: Structure-based pharmacophore modeling integrated with validated QSAR analysis was implemented to discover structurally novel SIRT2 inhibitors from the natural products database. The targeted QSAR model combined molecular descriptors with structure-based pharmacophore capable of explaining bioactivity variation of structurally diverse SIRT2 inhibitors. Manually built pharmacophore model, validated with receiver operating characteristic curve, and selected using the statistically optimum QSAR equation, was applied as a 3Dsearch query to mine AnalytiCon Discovery database of natural products.
Results: Experimental in vitro testing of highest-ranked hits identified asperphenamate and salvianolic acid B as active SIRT2 inhibitors with IC50 values in low micromolar range.
Conclusion: New chemical scaffolds of SIRT2 inhibitors have been identified that could serve as a starting point for lead-structure optimization.
Export Options
About this article
Cite this article as:
Khanfar A. Mohammad*, Alqtaishat Saja , Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure- Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (16) . https://dx.doi.org/10.2174/1871520621666210112121523
DOI https://dx.doi.org/10.2174/1871520621666210112121523 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor metastasis ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Metalloenzymes and Cancer: Μetalloenzyme Ιnhibitors and Artificial Metalloenzymes as anti-cancer agents
Metalloenzymes are enzymes containing metal ions, which are directly bound to the enzyme and play a role in promoting catalysis. About one-third of all enzymes known so far are metalloenzymes [1]. Metalloenzymes are central to a wide range of essential biological activities, including nucleic acid modification, protein degradation, and many ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Nutritional Therapy Strategies Targeting Tumor Energy Metabolism
Current Drug Metabolism Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Muscular Dystrophies: Histology, Immunohistochemistry, Molecular Genetics and Management
Current Pharmaceutical Design Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Physical Characterisation and Stability Study of Formulated <i>Chromolaena odorata</i> Gel
Current Drug Delivery Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes
Anti-Cancer Agents in Medicinal Chemistry The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Melting Profiles May Affect Detection of Residual HPV L1 Gene DNA Fragments in Gardasil<sup>®</sup>
Current Medicinal Chemistry Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets Role of Oxidative Stress in Hepatitis C Virus Induced Hepatocellular Carcinoma
Current Cancer Drug Targets Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews CAD System Design for Pituitary Tumor Classification based on Transfer Learning Technique
Current Medical Imaging Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies
Current Drug Targets PPARγ Agonists in Combination Cancer Therapies
Current Cancer Drug Targets Current Perspectives in the Application of Medicinal Plants Against Cancer: Novel Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry The Value of Emerging Prostate Cancer-associated lncRNA PCGEM1 in Various Tumors
Mini-Reviews in Medicinal Chemistry Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Ipilimumab and Vemurafenib: Two Different Routes for Targeting Melanoma
Current Cancer Drug Targets